N-SIDE launches Production App to optimise clinical manufacturing process
The software consulting company claims its software solution has already saved one pharma company €10.5 million
Life sciences software consulting company N-SIDE has launched a Production App which it says will further enhance end-to-end clinical trial supply chain management by optimising the pharmaceutical manufacturing process for entire clinical programmes, from drug substance through to drug product and investigational medicinal product.
The company said that with clinical trial supply chains being notoriously difficult to manage due to constantly changing information and large uncertainty in clinical trial demand, multiple teams and siloed data, the new software solution can solve these challenges by considering "all the manufacturing constraints specific to each clinical manufacturing program to deliver the optimal plan and budget."
According to N-SIDE, the app automatically optimizes the usage of production assets and resources to reduce waste, budget and timelines and then facilitates communication of any changes to all stakeholders, worldwide.
"What-if scenario planning allows teams to understand how individual changes might affect the overall situation and proactively model different scenarios to design the optimal plan," N-SIDE said. "With readily available, accurate data, managers can make informed decisions and rapidly adapt to ever-changing clinical plans."
Explaining the app's capability, the company's Life Sciences Director Sébastien Coppe said the app "connects the dots between the strategic vision and the operational decisions for planning your clinical program manufacturing."
N-SIDE said its app has already been tested by a large pharmaceutical company to optimize the clinical trials manufacturing plan for a key biological compound, resulting in an 11% decrease -- or €10.5-million -- in manufacturing costs.
The company added that with ever-changing supply needs and long manufacturing lead times, it is extremely difficult for clinical managers to plan manufacturing to meet these highly variable needs while also minimizing waste, controlling costs and reducing the risk of disrupted drug supply.
"At a program level, this is particularly challenging as multiple trials need to be considered in different global locations, often with a lack of standardization in ways of working and out-of-date or unreliable data on which to base decisions," N-SIDE said.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance